RedHill Biopharma surges after FDA approves stomach infection drug
04/11/2019 12:43
** U.S.-listed shares of Israel-based drugmaker RDHL.O up
24.7% at $8.58 premarket
** Co receives FDA approval for Talicia, an oral combination
drug targeting Helicobacter pylori (H. pylori) infection
urn:newsml:reuters.com:*:nL3N27K22U
** Co plans to launch Talicia in the first qtr of 2020
** H. pylori is a bacterial stomach infection which affects
about 35% of U.S. adult population and may lead to gastric
diseases, ulcers and cancers
** Stock up ~24.7% YTD as of Friday's close
(Reporting by Ruhi Soni)
((Ruhi.Soni@thomsonreuters.com;))